<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161457</url>
  </required_header>
  <id_info>
    <org_study_id>JHL-CLIN-1101-01</org_study_id>
    <nct_id>NCT03161457</nct_id>
  </id_info>
  <brief_title>A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 Versus EU-sourced MabThera® in Anti TNF Inadequate Responder Patients With Moderate to Severe Rheumatoid Arthritis (RA) on Background Methotrexate (MTX) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHL Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JHL Biotech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomised, double-blind, parallel group study to compare the
      pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, safety, tolerability and
      efficacy of JHL1101 versus MabThera in subjects with moderate to severe RA who have
      previously failed at least 1 tumour necrosis factor alpha (TNF) inhibitor (i.e., intolerance
      or documented active disease despite at least 12 weeks treatment according to the TNF
      inhibitor-approved treatment and dosage), and are on concomitant treatment with MTX.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will take place across approximately 31 centres across 12 countries and will
      randomise approximately 150 subjects as outpatients.

      The primary objective is to investigate and compare the pharmacokinetic profiles of JHL1101
      and MabThera (rituximab). The secondary objectives are to investigate the safety,
      tolerability, and immunogenicity of JHL1101 versus MabThera, to investigate the
      pharmacodynamics profile of JHL1101 versus MabThera, and investigate the efficacy of JHL1101
      versus MabThera.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration versus time curve</measure>
    <time_frame>Week 2 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events (safety)</measure>
    <time_frame>Until End-of-Study follow-up at Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline, Weeks 12, 16, 24, and 52</time_frame>
    <description>Human anti-chimeric antibody analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the depletion-time curve of CD19+ B-cell</measure>
    <time_frame>Day 0 to Day 15, Day 0 to Week 12, Day 0 to Week 24, and Day 0 to Week 52 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 0 through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) criteria 20, 50, 70 response rate</measure>
    <time_frame>Weeks 4, 8, 12, 16, 24 and 52 and over time from Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen and tender joint count</measure>
    <time_frame>From Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of arthritis pain</measure>
    <time_frame>From Baseline to Week 52</time_frame>
    <description>2010 ACR/European League Against Rheumatism (EULAR) Classification Criteria for RA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>JHL1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JHL1101</intervention_name>
    <description>1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration</description>
    <arm_group_label>JHL1101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration</description>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe active RA

          -  Documented intolerance to or inadequate response to at least 12 weeks of treatment
             with the licensed regimen of at least one TNF inhibitor therapy

          -  Women of childbearing potential must use a medically acceptable means of birth control
             and agree to continue its use during the study and for at least twelve months after
             the last dose of study drug.

        Exclusion Criteria:

          -  History of a severe allergic reaction or anaphylactic reaction to a biological agent
             or history of hypersensitivity to any component of the study drug including known
             hypersensitivity or allergy to a murine product

          -  Class IV as per the Classification of Global Functional Status in Rheumatoid Arthritis
             or wheelchair/bed-bound

          -  Have any significant systemic involvement with RA such as vasculitis, pulmonary
             fibrosis or Felty's syndrome

          -  History of or current inflammatory joint disease other than RA or other systemic
             disorder where the treatment or current or potential symptoms could confound the
             assessment of RA, with the exception of secondary Sjögren's syndrome

          -  Concomitant or recent DMARD treatments for RA

          -  Oral corticosteroids &gt;10mg/day prednisone equivalent or dose which has not been stable
             for the 4 weeks prior to Baseline

          -  Receipt of an intra-articular or other injectable corticosteroid within 4 weeks prior
             to Screening

          -  Intolerance or contraindications to IV corticosteroids

          -  Use of NSAIDs which have not been at a stable dose within 2 weeks prior to Baseline.

          -  Have undergone surgical treatments for RA including synovectomy and arthroplasty in
             more than 3 joints and/or within the last 8 weeks prior to Screening

          -  History of major surgery within the 12 weeks prior to Screening

          -  History of an infected joint prosthesis which subsequently has not been surgically
             removed/replaced

          -  Positive serological test for HBsAg, hepatitis B core antibody or hepatitis C
             serology.

          -  History of HIV infection, or a positive test at Screening

          -  History of tuberculosis (TB) infection.

          -  Acute clinical manifestations of herpes zoster virus or herpes simplex.

          -  Active infection of any kind or any major episode of infection requiring
             hospitalization within 24 week prior to Baseline or requiring treatment with IV
             anti-infective agents within 8 weeks prior to Baseline or oral anti infective agents
             within 2 weeks prior to Baseline

          -  Subjects at risk of progressive multifocal leukoencephalopathy (PML) as per protocol

          -  Any significant cardiac disease

          -  Subjects with a history of solid-organ transplantation

          -  History of lympho- or myeloproliferative disorder or malignancy within the last 5
             years

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Pang, PhD</last_name>
    <phone>(886) 3 658 3899</phone>
    <phone_ext>797</phone_ext>
    <email>ppang@jhlbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Chen</last_name>
    <phone>(886) 3 658 3899</phone>
    <phone_ext>798</phone_ext>
    <email>aychen@jhlbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Bijeljina</city>
        <zip>76300</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chen Alice</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Praha</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Bad Doberan</city>
        <zip>18209</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-420</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Kazan'</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Yaroslavl'</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Kyyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>L'viv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JHL Biotech Investigational Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Chen</last_name>
      <phone>(886) 3 658 3899</phone>
      <phone_ext>798</phone_ext>
      <email>aychen@jhlbiotech.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <keyword>Moderate RA</keyword>
  <keyword>Moderate Rheumatoid Arthritis</keyword>
  <keyword>Severe RA</keyword>
  <keyword>Severe Rheumatoid Arthritis</keyword>
  <keyword>Moderate to Severe RA</keyword>
  <keyword>Moderate to Severe Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

